AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.
Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
Lloyds is riding high, but allure of global stage could prove enough to entice António Horta-Osório away from comfortable gigLloyds Banking Group’s bad and impaired loans stand at historically low levels. Its net interest margin – the best measure of a bank’s profitability – is the highest in the UK sector, and still rising. It is generating capital faster than expected. The end is in sight on PPI provisions. And the state’s stake has been reduced to 2%, with the last of the shares to be sold in coming weeks. A good moment, then, for chief executive António Horta-Osório to bow out after six years at the helm? Horta-Osório says he’s happy in his post and there is more to do. Not everybody is convinced by that answer, since six years counts as a long innings for a FTSE 100 chief executive and he’s constantly linked with the vacancy at HSBC. An exit can’t be ruled out. But, actually, committing to a couple more laps of the track at Lloyds is surely a highly attractive prospect. With a 25% share of the UK retail market, the bank is currently playing in a league of its own and can expect to do so for years. Continue reading...
Фондовые индексы стран Западной Европы опускаются в начале торгов в четверг, инвесторы ждут заседания Европейского центрального банка (ЕЦБ) и оценивают отчетность крупных европейских компаний.
Inovio Pharmaceuticals (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.
Что привлекает игроков big pharma на рынке препаратов от неалкогольного стеатогепатита, где все еще нет ни одного официально одобренного лекарства?
IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.
Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.
Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.